Attention Repros Therapeutics, Inc. Investors: Law Firm Investigates on Behalf of Shareholders

Robbins LLP are investigating potential violations of federal securities laws on behalf of investors of Repros Therapeutics, Inc. (NASDAQ: RPRX). Repros Therapeutics is a development stage biopharmaceutical company, engaged in the development of new drugs to treat hormonal and reproductive system disorders.

Repros Shares Fall Sharply on FDA Concerns Over the Adequacy of Androxal Studies

Shares of Repros fell $6.57, or 27%, to close at $17.12 on October 23, 2013, following the company's announcement that the U.S. Food and Drug Administration had raised concerns regarding the reliability of clinical data connected its Androxal's Phase III pivotal efficacy study. On October 22, 2013, Repros revealed that it had been instructed by the FDA to request a meeting to discuss the adequacy of its clinical studies ZA-301 and ZA-302. In addition, the FDA would require Repros to submit additional study data for Androxal, delaying the submission of the company’s New Drug Application until at least the third or fourth quarter of 2014. As recently as September 18, 2013, Repros had expressed confidence that all data entered into the data base for study ZA-301 could pass FDA inspection.

Repros Shareholders Are Encouraged to Contact Shareholder Rights Law Firm Robbins

If you invested in Repros and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, or you can complete the form below and we will contact you directly.